衆生藥業(002317.SZ):獲得《藥品註冊證書》
格隆匯7月1日丨衆生藥業(002317.SZ)公佈,近日收到國家藥品監督管理局覈準簽發的環孢素滴眼液(III)及複方託吡卡胺滴眼液《藥品註冊證書》。環孢素滴眼液(III)臨牀用於治療4歲及以上兒童和青少年的嚴重性春季角結膜炎,相同產品在全球獲批的適應症包括結膜炎和乾眼症。複方託吡卡胺滴眼液臨牀用於診斷及治療爲目的的散瞳和調節麻痹,廣泛用於眼底病篩查、近視篩查,以及兒童青少年假性近視預防與治療中,爲睫狀肌麻痹驗光專家共識及假性近視診療指南推薦用藥,具有較高臨牀地位。複方託吡卡胺滴眼液屬於醫保乙類藥品,其安全性和有效性已得到臨牀廣泛驗證。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.